Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot StudyRobert R. Henry, Steven C. Griffen, Steven V. Edelman et al.|Diabetes Care|2014Cited by 238